Good News, Orphan Drug Status Granted By The FDA For Ezurpimtrostat, a Cutting Edge Drug For Liver Cancer!
The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).